Olanzapine pamoate injection -- experience and case reports from Hungarian clinical practice
When treating schizophrenia and other psychotic disorders, clinicians often encounter the problems of non-adherence, which is almost the most common drawback of achieving remission and a better quality of life. The uncertain oral drug taking habits may lead to relapses and rehospitalizations. Using second generation long acting injectables we have more possibilities to avoid these problems. This review attempts to present and describe the pharmacological background of the modern long acting injectables including patient cases where olanzapine pamoate long acting injectable provided remission and better quality of life for the patients.
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2013 |
|---|---|
| Erschienen: |
2013 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:15 |
|---|---|
| Enthalten in: |
Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology - 15(2013), 2 vom: 21. Juni, Seite 105-17 |
| Sprache: |
Ungarisch |
|---|
| Weiterer Titel: |
Olanzapin pamoát injekció -- tapasztalatok és esettanulmányok a hazai klinikai gyakorlatból |
|---|
| Beteiligte Personen: |
Sümegi, András [VerfasserIn] |
|---|
| Themen: |
12794-10-4 |
|---|
| Anmerkungen: |
Date Completed 30.10.2013 Date Revised 03.12.2018 published: Print Citation Status MEDLINE |
|---|
| Förderinstitution / Projekttitel: |
|
|---|
| PPN (Katalog-ID): |
NLM228812399 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM228812399 | ||
| 003 | DE-627 | ||
| 005 | 20231224080751.0 | ||
| 007 | tu | ||
| 008 | 231224s2013 xx ||||| 00| ||hun c | ||
| 028 | 5 | 2 | |a pubmed24n0762.xml |
| 035 | |a (DE-627)NLM228812399 | ||
| 035 | |a (NLM)23817361 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a hun | ||
| 100 | 1 | |a Sümegi, András |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Olanzapine pamoate injection -- experience and case reports from Hungarian clinical practice |
| 246 | 3 | 3 | |a Olanzapin pamoát injekció -- tapasztalatok és esettanulmányok a hazai klinikai gyakorlatból |
| 264 | 1 | |c 2013 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a Date Completed 30.10.2013 | ||
| 500 | |a Date Revised 03.12.2018 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a When treating schizophrenia and other psychotic disorders, clinicians often encounter the problems of non-adherence, which is almost the most common drawback of achieving remission and a better quality of life. The uncertain oral drug taking habits may lead to relapses and rehospitalizations. Using second generation long acting injectables we have more possibilities to avoid these problems. This review attempts to present and describe the pharmacological background of the modern long acting injectables including patient cases where olanzapine pamoate long acting injectable provided remission and better quality of life for the patients | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 7 | |a Antipsychotic Agents |2 NLM | |
| 650 | 7 | |a Delayed-Action Preparations |2 NLM | |
| 650 | 7 | |a Hypnotics and Sedatives |2 NLM | |
| 650 | 7 | |a Benzodiazepines |2 NLM | |
| 650 | 7 | |a 12794-10-4 |2 NLM | |
| 650 | 7 | |a Olanzapine |2 NLM | |
| 650 | 7 | |a N7U69T4SZR |2 NLM | |
| 700 | 1 | |a Kálmán, János |e verfasserin |4 aut | |
| 700 | 1 | |a Csekey, László |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neuropsychopharmacologia Hungarica : a Magyar Pszichofarmakologiai Egyesulet lapja = official journal of the Hungarian Association of Psychopharmacology |d 2004 |g 15(2013), 2 vom: 21. Juni, Seite 105-17 |w (DE-627)NLM148164447 |x 1419-8711 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2013 |g number:2 |g day:21 |g month:06 |g pages:105-17 |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2013 |e 2 |b 21 |c 06 |h 105-17 | ||